FY2028 EPS Estimates for Envista Boosted by Leerink Partnrs

Envista Holdings Corporation (NYSE:NVST - Free Report) - Stock analysts at Leerink Partnrs boosted their FY2028 earnings per share estimates for shares of Envista in a report issued on Monday, July 14th. Leerink Partnrs analyst M. Cherny now anticipates that the company will post earnings of $1.47 per share for the year, up from their previous estimate of $1.45. The consensus estimate for Envista's current full-year earnings is $1.00 per share.

A number of other research firms have also issued reports on NVST. Bank of America dropped their target price on Envista from $26.00 to $23.00 and set a "buy" rating on the stock in a report on Tuesday, April 29th. Robert W. Baird raised Envista from a "neutral" rating to an "outperform" rating and boosted their target price for the company from $21.00 to $23.00 in a report on Tuesday, May 27th. Morgan Stanley set a $16.00 target price on Envista in a report on Tuesday, April 15th. UBS Group dropped their target price on Envista from $21.00 to $18.00 and set a "neutral" rating on the stock in a report on Monday, May 5th. Finally, Baird R W raised Envista from a "hold" rating to a "strong-buy" rating in a report on Tuesday, May 27th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $20.23.

Envista Stock Performance

Shares of NVST stock traded down $0.29 during midday trading on Thursday, hitting $19.46. The company had a trading volume of 1,980,932 shares, compared to its average volume of 2,461,826. The stock has a market cap of $3.30 billion, a price-to-earnings ratio of -2.98, a PEG ratio of 1.25 and a beta of 1.00. The company has a debt-to-equity ratio of 0.43, a current ratio of 2.12 and a quick ratio of 1.82. The company's 50 day simple moving average is $18.87 and its 200 day simple moving average is $18.53. Envista has a 52-week low of $14.22 and a 52-week high of $23.00.

Envista (NYSE:NVST - Get Free Report) last posted its earnings results on Thursday, May 1st. The company reported $0.24 earnings per share for the quarter, beating the consensus estimate of $0.20 by $0.04. The business had revenue of $616.90 million during the quarter, compared to the consensus estimate of $608.17 million. Envista had a positive return on equity of 4.07% and a negative net margin of 44.90%. The business's quarterly revenue was down 1.1% on a year-over-year basis. During the same period in the previous year, the business earned $0.26 EPS.

Hedge Funds Weigh In On Envista

Several institutional investors and hedge funds have recently added to or reduced their stakes in NVST. GAMMA Investing LLC grew its holdings in shares of Envista by 1,338.3% in the 1st quarter. GAMMA Investing LLC now owns 33,139 shares of the company's stock worth $572,000 after acquiring an additional 30,835 shares during the period. Two Sigma Advisers LP grew its holdings in shares of Envista by 66.6% in the 4th quarter. Two Sigma Advisers LP now owns 47,800 shares of the company's stock worth $922,000 after acquiring an additional 19,100 shares during the period. Comerica Bank grew its holdings in shares of Envista by 8.2% in the 4th quarter. Comerica Bank now owns 121,851 shares of the company's stock worth $2,350,000 after acquiring an additional 9,248 shares during the period. Wealth Enhancement Advisory Services LLC grew its holdings in shares of Envista by 220.5% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 47,319 shares of the company's stock worth $817,000 after acquiring an additional 32,556 shares during the period. Finally, Norges Bank acquired a new stake in shares of Envista in the 4th quarter worth approximately $38,052,000.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.